Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AmpliMed Corporation |
---|---|
Information provided by: | AmpliMed Corporation |
ClinicalTrials.gov Identifier: | NCT00327249 |
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: imexon |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma |
Study Start Date: | October 2005 |
Study Completion Date: | January 2008 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
Investigational Site 025 | |
Little Rock, Arkansas, United States, 72206 | |
United States, Texas | |
Investigational Site 008 | |
Houston, Texas, United States, 77030 |
Responsible Party: | AmpliMed ( Evan Hersh ) |
Study ID Numbers: | AMP-007 |
Study First Received: | May 17, 2006 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00327249 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Immunoproliferative Disorders Hemorrhagic Disorders Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders Vascular Diseases |
Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Blood Protein Disorders Hematologic Diseases Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Neoplasms Hemorrhagic Disorders Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |